Femasys Inc. - Common Stock (FEMY)

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.

FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.

Gainers Maris-Tech Ltd. (NASDAQ: MTEK) shares rose 38% to $1.38 in pre-market trading, after gaining 6% on Friday. Maris-Tech, on Friday, disclosed the launch of Jupiter Drones, an innovative, drone-oriented solution based on Maris-Tech's Jupiter Nano platform.

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems.